Skye Bioscience, Inc. has appointed Keith W. Ward, PhD, to its board of directors and promoted Tu Diep, MSc to Chief Development Officer, effective immediately. Keith W. Ward, PhD, is a life sciences executive with over 25 years of experience in the biotech and pharmaceutical industry. Dr. Ward currently serves as President and Chief Executive Officer of InterveXion Therapeutics. Prior to joining InterveXion, Dr. Ward served as Executive Vice President and Chief Development Officer for Reata Pharmaceuticals. Mr. Diep most recently served as Senior Vice President of Development at Skye. As CDO, Mr. Diep is primarily responsible for overseeing and executing Skye's research strategy, advancing discovery programs through target validation, and leading optimization toward development candidate nominations and IND filings.